Form 4: Voyager Therapeutics Director Catherine J. Mackey Acquires 24,000 Stock Options

Director Catherine J. Mackey acquired 24,000 stock options in Voyager Therapeutics, Inc. on June 5, 2024, according to a Form 4 filing.

Summary

• Catherine J. Mackey, a director of Voyager Therapeutics, Inc., acquired 24,000 stock options on June 5, 2024.
• The options were granted under the company's 2015 Stock Option and Incentive Plan, as part of the director compensation policy.
• The exercise price of the stock options is $8.7.
• The options vest upon the earlier of the one-year anniversary of the grant date or the date of the next annual meeting of stockholders, contingent upon continued service as a director.
• The expiration date for the options is June 5, 2034.

Sentiment

Score: 7

Explanation: The document reflects a routine director compensation event, which is generally viewed neutrally to positively as it aligns director interests with shareholder value. The sentiment is slightly positive due to the incentive alignment.

Positives

• The grant of stock options aligns the director's interests with those of the shareholders.
• The vesting schedule incentivizes continued service as a director.

Industry Context

Stock option grants are a common form of executive and director compensation in the biotechnology industry, aligning their interests with the long-term performance of the company.

Comparison to Industry Standards

• Stock option grants to directors are a standard practice in publicly traded companies, particularly in the biotech sector.
• The vesting schedule of one year or until the next annual meeting is typical for director equity grants.
• The exercise price is set at $8.7.

Stakeholder Impact

• The stock option grant aligns the director's interests with those of the shareholders, potentially encouraging decisions that increase shareholder value.

Key Dates